The creation of effective vaccines and therapies for human parainfluenza virus (HPIV) infections remains a challenging but a necessary task. By leveraging our expertise and state-of-the-art facilities, our company is poised to lead the charge in HPIV vaccine and therapy development.
Overview of Human Parainfluenza Virus Infection
Human parainfluenza virus infection is an important respiratory pathogen affecting everyone from infants to the elderly as well as the immunocompromised. The HPIV viruses are classified as enveloped single stranded RNA viruses of the Paramyxoviridae family and are divided into 4 major types : HPIV – 1, HPIV – 2, HPIV – 3 and HPIV – 4. This group of viruses infects the respiratory tract causing croup, laryngitis, croup, bronchitis and pneumonia. In children below five years of age, HPIV infections are responsible for the highest proportion of hospitalizations, preceded only by Respiratory Syncytial Virus infection.
Fig.1 Schematic diagram of parainfluenza virus 5 (PIV5) genomes and virus rescue. (Chen Z., et al., 2018)
Vaccine Development for Human Parainfluenza Virus Infection
Live-Attenuated Vaccines
Live-attenuated vaccines are composed of an altered version of a virus that lacks the potential to cause harm but has the ability to stimulate a response. The bovine PIV-3 (bPIV-3) vaccine is an example of such a vaccine and clinical studies support its efficacy as a safe vaccine which is capable of evoking an immune response.
Recombinant Vaccines
With the use of rDNA technology, vaccines that express certain HPIV antigens have been developed. One such candidate is the cDNA recominant rHPIV3cp45 vaccine, which has been through I phase trials and was found to be safe and immunogenic in infants and young children.
Quadrivalent Vaccines
In regard to quadrivalent vaccines the intention is to create wide protection system against the four types of human parainfluenza virus (HPIV). These vaccines necessitate the modification of viral's fusion (F) glycoprotein to be in a prefusion form as it capable of eliciting better neutralizing antibody responses.
Therapeutics Development for Human Parainfluenza Virus Infection
Ribavirin, which is a nucleoside analogue, has been used for the therapeutic of severe HPIV infections in immunocompromised individuals; however, this treatment is off label. Even though it appears to have some effectiveness, concerns regarding safety and taking the drug by means of aerosol nebulizer restrict its use.
DAS181 is a new antiviral drug directed against hemagglutinin-neuraminidase (HN) protein of HPIV that prevents the pathogen from binding with the host cell. It seems to have been effective treating severe HPIV infections during clinical trials, as it provides a targeted therapeutic approach without the use of viruses.
Our Services
In respect to HPIV infection, our company employs advanced technologies and scientific research in the creation of vaccines and therapies' that caters to the exaggerated needs of this domain.
Disease Models
- IFNα/β and IFNγ Double Knockout Models (AG129 Mice)
- Hamster HPIV-3 Infection Models
- Guinea Pig Respiratory Tract Infection Models
- Cotton Rat HPIV Infection Models
For the development of the HPIV vaccine and therapy, our preclinical research services seek to solve the specific problems it faces. We provide a host of services which are as follows:
- Immunogenicity Studies: Test the immunogenic potential of vaccine candidates in animal models for efficacy evaluation.
- Safety Assessments: Carry out thorough safety assessments to protect the subjects involved in vaccine trials.
- Pharmacodynamics and Pharmacokinetics: Study the action and distribution of antiviral agents to formulate the drugs' dosing schedules.
- Pathogenesis Studies: Determine the viral pathogenesis of HPIV for vaccine and therapeutic development.
If you are interested in our services, please feel free to contact us.
References
- Chen, Zhenhai. "Parainfluenza virus 5–vectored vaccines against human and animal infectious diseases." Reviews in medical virology 28.2 (2018): e1965.
- Pawełczyk, Malgorzata, and Marek Leszek Kowalski. "The role of human parainfluenza virus infections in the immunopathology of the respiratory tract." Current allergy and asthma reports 17 (2017): 1-10.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
